Skip to content
AnalystLens

Labcorp Holdings 8-K Report, Financial Results (Jul 30, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 30, 2026
Period End
July 30, 2026
Security
LH
In the record · 2016–202610-K1310-Q338-K382

LH filed 13 annual reports (10-K), 33 quarterly reports (10-Q) and 382 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Apr ’17Apr ’17
  2. Leadership change8-K · Jun ’19Jun ’19
  3. Material agreement8-K · May ’21May ’21
  4. Material agreement8-K · Jun ’25Jun ’25

01—Abstract

Summary

Summary of the 8-K filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Labcorp Holdings Inc. (NYSE: LH) furnished an 8-K on July 30, 2026, under Item 2.02 (Results of Operations and Financial Condition), attaching a press release announcing its second quarter 2026 results and raising its full-year 2026 guidance.

Second-quarter revenue was $3.73 billiona versus $3.53 billion a year earlier, up 5.8%. Diluted EPS was $3.64 versus $2.84, and adjusted EPS was $4.99 versus $4.35, up 14.9%. Operating income was $451.6 million, and adjusted operating income was $588.7 million, or 15.8% of revenue versus 15.1% a year earlier.

Free cash flow for the quarter was $313.9 millionb, compared with $542.7 million a year earlier, which the company attributed primarily to working capital timing and planned increases in capital expenditures. The company raised its 2026 enterprise revenue guidance to $14,710 million to $14,827 million (5.4% to 6.3% growth) and its adjusted EPS guidance to $18.10 to $18.55, up 30 cents at the midpoint. Free cash flow guidance was unchanged at $1,240 million to $1,360 million.

Segment results were mixed in detail: Diagnostics Laboratories revenue rose 5.5% with adjusted operating margin of 18.0%, while Biopharma Laboratory Services revenue rose 6.5% with adjusted operating margin of 17.0%. Capital allocation was active during the quarter. Labcorp invested $225.7 millionc in acquisitions, repurchased $353.8 million of stock, paid $58.7 million in dividends, and retired $500.0 million of senior notes in June.

In July the Board approved a $1.0 billiond increase in the share repurchase authorization, bringing the remaining total to $1.4 billion. Total debt at quarter-end was $5.86 billion against cash of $141.8 million.

02—Key points

Key Highlights

  1. Q2 2026 revenue of $3.73 billion, up 5.8% from $3.53 billion; organic growth was 4.2%, with acquisitions contributing 1.2% and foreign exchange 0.4%.
  2. Q2 2026 diluted EPS of $3.64 versus $2.84, and adjusted EPS of $4.99 versus $4.35, up 14.9%.
  3. Full-year 2026 enterprise revenue guidance raised to $14,710–$14,827 million (5.4%–6.3% growth) and adjusted EPS guidance raised to $18.10–$18.55, up 30 cents at the midpoint.
  4. Free cash flow for Q2 2026 was $313.9 million, down from $542.7 million, mainly due to working capital timing and higher capital expenditures; full-year free cash flow guidance held at $1,240–$1,360 million.
  5. Board approved a $1.0 billion increase in the share repurchase authorization in July, leaving $1.4 billion remaining.
  6. Diagnostics Laboratories adjusted operating margin reached 18.0% (up from 17.6%), and Biopharma Laboratory Services adjusted operating margin reached 17.0% (up from 15.7%).
  7. Biopharma backlog stood at $8.73 billion as of June 30, 2026, with trailing-twelve-month book-to-bill of 1.03.

03—Questions

Frequently Asked Questions

  1. How did Labcorp perform in the second quarter of 2026?

    Revenue rose 5.8% to $3.73 billion, adjusted operating margin expanded to 15.8% from 15.1%, and adjusted EPS grew 14.9% to $4.99. Diluted EPS was $3.64 versus $2.84 a year earlier.

  2. What changed in full-year 2026 guidance?

    Enterprise revenue guidance was raised to $14,710–$14,827 million from $14,649–$14,803 million, implying 5.4%–6.3% growth. Adjusted EPS guidance was raised to $18.10–$18.55 from $17.70–$18.35. Free cash flow guidance was unchanged at $1,240–$1,360 million.

  3. Why did free cash flow decline in the quarter?

    Free cash flow was $313.9 million versus $542.7 million a year earlier. The company attributed the difference primarily to working capital timing and planned increases in capital expenditures, which were $131.6 million in the quarter versus $77.9 million.

  4. What did Labcorp do with its capital in the quarter?

    Labcorp invested $225.7 million in acquisitions, repurchased $353.8 million of stock, paid $58.7 million in dividends, and retired $500.0 million of senior notes in June. A quarterly dividend of $0.72 per share was declared, payable September 11, 2026.

  5. What is the company's debt and liquidity position?

    At June 30, 2026, cash and cash equivalents were $141.8 million and total debt was $5.86 billion, according to the capital allocation summary in the press release.

04—Continue

← View all 8-K filings